Targeting Na+ /K+ -ATPase by berbamine and ouabain synergizes with sorafenib to inhibit hepatocellular carcinoma.

Songpeng YangShu YangHongying ZhangHui HuaQingbin KongJiao WangYangfu Jiang

Published in: British journal of pharmacology (2021)

Berbamine or other Na+ /K+ -ATPase ligands have a potential for improving sorafenib responsiveness in hepatocellular carcinoma. Targeting Na+ /K+ -ATPase represents a novel strategy to potentiate the anti- hepatocellular carcinoma effects of sorafenib.

Keyphrases

cancer therapy
endoplasmic reticulum
drug delivery